this work, for clinical applications as potential theranostic agents in SARS-CoV-2 infection. Author Contributions Conceptualization: Faryal Mehwish Awan, Burton B. Yang. Data curation: Hassan Ayaz ... , Nouman Aslam, Badr Alzahrani, Muhammad Arif. 21 / 26 Formal analysis: Hassan Ayaz, Nouman Aslam, Faryal Mehwish Awan, Rabea Basri. Funding acquisition: Badr Alzahrani, Sadiq Noor Khan. Methodology: Hassan
A regulated immune system employs multiple cell types, diverse variety of cytokines and interacting signalling networks against infections. Systems biology offers a promising solution to model and simulate such large populations of interacting components of immune systems holistically. This study focuses on the distinct components of the adaptive immune system and analysis, both...
Hepatitis C virus (HCV) vaccines, designed to augment specific T-cell responses, have been designated as an important aspect of effective antiviral treatment. However, despite the current satisfactory progress of these vaccines, extensive past efforts largely remained unsuccessful in mediating clinically relevant anti-HCV activity in humans. In this study, we used a series of...
Informatics Approaches Amna Younus Saba Munawar Muhammad Faraz Bhatti Aqsa Ikram Faryal Mehwish Awan Ishrat Jabeen Nasar Virk Hussnain Ahmed Janjua Muhammad Arshad Polio viral proteinase 2A performs
AuthorsSearch for Faryal Mehwish Awan in:Nature Research journals • PubMed • Google Scholar Search for Anam Naz in:Nature Research journals • PubMed • Google Scholar Search for Ayesha Obaid in:Nature Research
Circular RNAs are a class of non-coding RNAs that are receiving extensive attention. Despite reports showing circular RNAs acting as microRNA sponges, the biological functions of circular RNAs remain largely unknown. We show that in patient tumor samples and in a panel of cancer cells, circ-Foxo3 was minimally expressed. Interestingly, during cancer cell apoptosis, the expression...
Hepatocellular carcinoma (HCC) is the world’s third most widespread cancer. Currently available circulating biomarkers for this silently progressing malignancy are not sufficiently specific and sensitive to meet all clinical needs. There is an imminent and pressing need for the identification of novel circulating biomarkers to increase disease-free survival rate. In order to...
TP53 mutations occur in many different types of cancers that produce mutant p53 proteins. The mutant p53 proteins have lost wild-type p53 activity and gained new functions that contribute to malignant tumor progression. Different p53 mutations create distinct profiles in loss of wild-type p53 activity and gain of functions. Targeting the consequences generated by the great number...
